Treatment Trajectories and Dose Optimization of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Real-World Landmark Analysis

Clicks: 1
ID: 318885
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #154 of 172 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 172 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Abrocitinib is an effective oral Janus kinase 1 inhibitor for moderate-to-severe atopic dermatitis (AD), although real-world evidence regarding dose optimization strategies remains limited. OBJECTIVES: To evaluate treatment trajectories and short-term clinical outcomes associated with abrocitinib dose maintenance, escalation, and step-down in routine clinical practice. METHODS: A retrospective single-center observational study was conducted including adult patients with moderate-to-severe AD treated with abrocitinib. A Week 16 (W16) landmark approach was used to classify patients into four treatment trajectories: maintenance of 200 mg, step-down from 200 mg to 100 mg, maintenance of 100 mg, and escalation from 100 mg to 200 mg. Clinical outcomes, including Eczema Area and Severity Index (EASI), pruritus Numerical Rating Scale (p-NRS), and Dermatology Life Quality Index (DLQI), were evaluated at W16 and W24. RESULTS: Among 58 patients included in the landmark analysis, 37 (63.8%) initiated abrocitinib 200 mg and 21 (36.2%) initiated 100 mg. Most patients maintained their starting dose through W16 (83.8% in the 200-mg group and 76.2% in the 100-mg group). Dose escalation from 100 mg to 200 mg occurred in 23.8% of patients and was exclusively driven by insufficient efficacy, whereas step-down from 200 mg to 100 mg occurred in 10.8% and was related to treatment-emergent tolerability concerns or clinical improvement. Clinically meaningful reductions in EASI, p-NRS, and DLQI were observed across all trajectory groups, without significant differences in W24 outcomes. CONCLUSIONS: In routine clinical practice, most patients maintained their initial abrocitinib dose, while dose optimization strategies appeared feasible in selected cases without compromising short-term disease control.
Reference Key
openalex_W7166159451 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors M A Napolitano, Chiara Palagiano, Cataldo Patruno, Martina Turco, Francesca di Vico, Luca Potestio
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag271
URL
https://doi.org/10.1093/ced/llag271
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.